Biora Therapeutics Shares Rise 64% After FDA Clears Application for Ulcerative Colitis Treatment

By Ben Glickman


Shares of Biora Therapeutics rose late Thursday after the company received clearance from the U.S. Food and Drug Administration to use its ulcerative colitis treatment in a...

Related Keywords

Ben Glickman ,Drug Administration ,Biora Therapeutics ,San Diego Based ,Dow Jones ,Markets ,